Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Laboratorios Farmaceuticos RoviLABFF 99 Earnings Yield (Joel Greenblatt) % is 8.10% as of Jun. 2026, which is 87% above its 10-year median of 4.34. GuruFocus rates LABFF with a GF Score™ of 99/100 and a GF Value™ of $85.89 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Laboratorios Farmaceuticos Rovi ranks better than 73.02% on this metric.
Laboratorios Farmaceuticos Rovi's Enterprise Value for the quarter that ended in Jun. 2026 was $4,629.5 Mil.
Laboratorios Farmaceuticos Rovi's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was $278.4 Mil. Laboratorios Farmaceuticos Rovi's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2026 was 8.10%.
The historical rank and industry rank for Laboratorios Farmaceuticos Rovi's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
LABFF'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 0.98 Med: 4.34 Max: 14.08
Current: 7.83
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Laboratorios Farmaceuticos Rovi was 14.08%. The lowest was 0.98%. And the median was 4.34%.
LABFF's Earnings Yield (Joel Greenblatt) % is ranked better than 73.02% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 3.17
vs LABFF: 7.83
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Laboratorios Farmaceuticos Rovi's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was 13.62%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorios Farmaceuticos Rovi's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laboratorios Farmaceuticos Rovi Earnings Yield (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Laboratorios Farmaceuticos Rovi's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Laboratorios Farmaceuticos Rovis Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
Laboratorios Farmaceuticos Rovi's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $278.4 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 8.10% mean?
Laboratorios Farmaceuticos Rovi (LABFF) has a Earnings Yield (Joel Greenblatt) % of 8.10% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. This is 87% above median its historical median of 4.34. Over the past decade, Laboratorios Farmaceuticos Rovi's Earnings Yield (Joel Greenblatt) % has ranged from 0.98 to 14.08. According to the industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #272 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 27%.
Is Laboratorios Farmaceuticos Rovi's Earnings Yield (Joel Greenblatt) % too high?
Laboratorios Farmaceuticos Rovi's current Earnings Yield (Joel Greenblatt) % of 8.10% is 87% above median its 10-year median of 4.34. Over the past 10 years, this metric has ranged from a low of 0.98 to a high of 14.08. The Drug Manufacturers industry median Earnings Yield (Joel Greenblatt) % is 3.17. Laboratorios Farmaceuticos Rovi's value of 8.10% is 155.5% above this industry median. Based on the distribution chart, Laboratorios Farmaceuticos Rovi ranks #272 out of 1008 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's Earnings Yield (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #272 out of 1008 companies for Earnings Yield (Joel Greenblatt) %. This puts Laboratorios Farmaceuticos Rovi in the upper half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 3.17. Laboratorios Farmaceuticos Rovi's value of 8.10% is 155.5% above this benchmark. Historically, Laboratorios Farmaceuticos Rovi's own Earnings Yield (Joel Greenblatt) % has ranged from 0.98 to 14.08 over the past decade. While the company's 10-year median is 4.34 vs. the industry median of 3.17, Laboratorios Farmaceuticos Rovi has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Drug Manufacturers company?
The median Earnings Yield (Joel Greenblatt) % among Drug Manufacturers companies is 3.17, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Laboratorios Farmaceuticos Rovi's current Earnings Yield (Joel Greenblatt) % of 8.10% is 155.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. For the Drug Manufacturers industry, the median Earnings Yield (Joel Greenblatt) % is 3.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Laboratorios Farmaceuticos Rovi's current Earnings Yield (Joel Greenblatt) % is 8.10%, which is 87% above median its own 10-year median of 4.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi (LABFF) is currently considered Modestly Undervalued. The stock's GF Value™ is $85.89, compared to a current price of $67.17 — trading 21.8% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 8.10%, which is 87% above median its 10-year median of 4.34 and 155.5% above the Drug Manufacturers industry median of 3.17. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 99/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (LABFF), the current Earnings Yield (Joel Greenblatt) % is 8.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laboratorios Farmaceuticos Rovi (LABFF) Overvalued in 2026?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be undervalued.
The current stock price of $67.17 is trading 21.8% below its estimated GF Value™ of $85.89.
GuruFocus considers Laboratorios Farmaceuticos Rovi to be Modestly Undervalued.
Key valuation signals for LABFF:
Earnings Yield (Joel Greenblatt) %: 8.10% (87% above median its 10-year median of 4.34)
GF Value™: $85.89 vs. price of $67.17 (21.8% below fair value)
Industry Position: 155.5% above the Drug Manufacturers median (#272 of 1008)
No single metric tells the full story. See the LABFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
99GF Score
Get the complete analysis for LABFF
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LABFF has been successfully added to your 
